Sunday, July 3, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

Lack of diversity in genomic research could deprive Africans of life-changing care for chronic diseases

by Medical Finance
in News
Scientists discover a division of labor between genetic switches
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

The lack of diversity in genomic research could mean Africans are missing out on potential life-changing care for chronic health disorders, according to a new study published in Nature Medicine.

Genetic risk scores are a tool used to estimate an individual’s risk of developing a disease, based on genetic factors. Researchers are able to find out someone’s genetic risk score by examining a population’s genetic data and linking genetic factors to various health outcomes to indicate how likely they are to experience certain conditions.

These genetic risk scores are thought to revolutionize medicine by making it possible for people to receive treatments in line with their genetic make up, as well as for early identification and prevention of diseases. However, due to the small numbers of genetic studies involving African people, there is not currently enough information to create accurate genetic risk scores to predict their vulnerability to illnesses such as heart diseases.

The study, led by researchers from the MRC/UVRI and the London School of Hygiene & Tropical Medicine (LSHTM) Uganda Research Unit  in collaboration with those from the University of Witwatersrand in South Africa, used genetic data from 1.4 million people of diverse ancestry across sub-Saharan Africa to examine how the use of diverse and representative data can impact our ability to predict disease risk.

The team found that when genetic data from the African American population was included in genomic studies, the genetic risk score estimates were five times more accurate for people with African ancestry, compared to when data from European ancestry was used.

African Americans only comprise 1.1% of global genomic studies. These findings emphasize the importance of including Africans’ genetic information in genomic studies in order to gain more accurate information about genetic risk factors for disease, and better control the growing trend of chronic health disorders in Africa.

Currently, genomic studies include primarily individuals with European ancestry. This means genetic risk scores in predicting risk of disease, while applicable to the European population, is not accurate or reliable for those of African ancestry. It is crucial that we address this lack of diversity in genomic data. More genomic research is required to produce genetic risk scores that are relevant and representative of the genetic diversity in African populations due to age, lifestyle, environment, and other genetic factors.”


Segun Fatumo, Associate Professor of Genetic Epidemiology & Bioinformatics at the MRC/UVRI and LSHTM Uganda Research Unit

Researchers used data from Uganda and South Africa to gather genetic information using genetic risk scores to identify people within continental African populations with high and low fat levels. Their findings identified a number of inherent features in African populations, including that the genetic risk scores were more accurate for people living in urban settings in South Africa than for those in Uganda, due to differences in age, lifestyles, environments and genetics.

Additionally, by including well-known risk factors, such as age, gender, body mass index (BMI) and type 2 diabetes in the estimation of genetic risk scores, the classification of people with either high or low risks improved by 42%.

This was in contrast to conventional risk factors reported in European-based studies such as age, gender, and body mass index as significant contributors to identifying people with high and low fat levels. These findings also demonstrate that a standard genetic risk score cannot be applied across different ethnicities and nations in Africa due to genetic variability and other factors which affect risk  such as age, lifestyle and environment.

The team also divided the population into three categories to indicate whether they have a low, medium or high risk of developing a disease. This could help clinicians and genetic specialists to evaluate an individual’s risk of disease, especially those at high risk of developing chronic diseases.

Early diagnosis and treatment is one of the best ways to reduce the chances of developing chronic diseases such as heart and blood vessel disorders. The lack of diversity in genetic studies, and those that include African people in particular, has slowed progress in calculating individuals’ susceptibility to illnesses, which in turn slows their path to diagnosis and treatment.

Although genetic risk scores are not extensively used by health professionals at the moment, the researchers believe these findings provide hope for enhancing clinical care in Africa. Knowing how likely an individual is to get a disease could help them take preventative steps to diagnose it earlier, when it is easier to treat, or even cure. According to the researchers, this is crucial for detecting those who are at risk of having high levels of body fat in the future.

Dr Tinashe Chikowore, from the University of the Witwatersrand and an author of this study, said: “Advocating for greater diversity in genetic studies will guarantee that Africa is not left out of future precision medicine initiatives, which are crucial in identifying people who are more or less susceptible to contract chronic infections.”

The research study was funded by the Medical Research Council and the Wellcome Trust.

Source:

London School of Hygiene & Tropical Medicine (LSHTM)

Journal reference:

Kamiza, A.B., et al. (2022) Transferability of genetic risk scores in African populations. Nature Medicine. doi.org/10.1038/s41591-022-01835-x.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Scientists shed light on placenta’s role in transferring vitamin D to fetus during pregnancy

Scientists use transcriptomics to explore the ancient origins of placenta

by Medical Finance
July 3, 2022
0

The fossil record tells us about ancient life through the preserved remains of body parts like bones, teeth and turtle...

Slight pH adjustment may turn a metabolic inhibiting drug into promising COVID-19 treatment

Study shows the effects of “forever chemicals” on soil structure and function

by Medical Finance
July 3, 2022
0

Soils are impacted globally by several anthropogenic factors, including chemical pollutants. Among those, perfluoroalkyl and polyfluoroalkyl substances (PFAS) are of...

Horizontal gene transfer between viruses and hosts plays a major role in driving evolution

Chemical-based sequencing method to efficiently study DNA methylation

by Medical Finance
July 3, 2022
0

One way cells can control the activities of their genes is by adding small chemical modifications to the DNA that...

Study: Cell culture model system utilizing engineered A549 cells to express high levels of ACE2 and TMPRSS2 for investigating SARS-CoV-2 infection and antivirals. Image Credit: Microgen / Shutterstock.com

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

by Medical Finance
July 3, 2022
0

In a study recently published on the bioRxiv* preprint server, researchers developed a human A549 lung epithelial cell-based model to...

Bacterial biofilms use a developmental patterning mechanism seen in plants and animals

Composition of poplar tree microbiome changes dramatically over time, study finds

by Medical Finance
July 3, 2022
0

The science Recent work shows that the plant microbiome-;the microorganisms in a plant and its immediate environment-;influences plant health, survival,...

Synexa Life Sciences Strengthens its Executive Team for Further Growth

Synexa Life Sciences Strengthens its Executive Team for Further Growth

by Medical Finance
July 3, 2022
0

 Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, announces its plans for growth and...

Next Post
Study: BNT162b2 vaccine boosts neutralizing antibodies to ancestral SARS-CoV-2 & Omicron variant in adults received 2-dose inactivated vaccine. Image Credit: Tamer Adel Soliman/Shutterstock

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Study: Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants. Image Credit: Tatiana Shepeleva/Shutterstock

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Chem Lab c618f8c3be2845828afd242b15eaaa94 620x480
    Novel plug-and-play multi-organ chip can be customized to the patient
  • shutterstock 532679098 573152c4350d4fe79b49ad0eacf10282 620x480
    KHN’s ‘What the Health?’: Contemplating a post-‘Roe’ world
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply